.png)
In the rapidly advancing realm of precision medicine, healthcare professionals (HCPs) are witnessing a transformative shift in their roles. This approach, which tailors treatment to the individual's genetic makeup, lifestyle, and environment, demands a new set of skills and knowledge from HCPs – including physicians, nurses, and pharmacists. They are now at the forefront of integrating complex genetic information into patient care, navigating ethical dilemmas, and maintaining an up-to-date understanding of technological innovations. This blog post explores how precision medicine is reshaping the responsibilities and expertise of HCPs, and what this means for patient care.
- Sano Genetics is the only software platform tailored to running precision medicine clinical trials, leveraging AI to manage all aspects from design to patient recruitment, to genetic and other biomarker testing and patient engagement
- Precision medicine is a fast-growing category - today more than 30% of trials are precision-driven which is predicted to reach 80% by the end of the decade
- Sano Genetics is experiencing huge demand for its product, experiencing 5x growth ARR year-on-year and now serving four of the major pharmaceutical companies
- New funding brings the total raised by the company to $22M to help it meet demand and further automate its processes
In the realm of healthcare, a pivotal shift is taking place: the growing collaboration between academia, biotechnology, and pharmaceutical industries in the field of precision medicine. This evolving partnership is more than a trend; it's transforming how we approach the development of new drugs and treatments.
In the ever-evolving field of rare disease research, it's crucial to remain informed about the latest progress. At Sano, our commitment is to stay ahead of these developments. We are excited to offer a curated overview of some of the most significant advancements in rare disease research from the past few months.
In the rapidly evolving world of healthcare, a profound transformation is taking place at the intersection of Artificial Intelligence (AI) and genomics. This convergence is not just a fleeting trend; it's a fundamental shift in how we approach medicine, diagnosis, and treatment. Our latest whitepaper explores this significant development, shedding light on how AI is unlocking new possibilities in genomic medicine.
Since the advent of precision medicine, there has been a noticeable shift in patient engagement and decision-making in healthcare. Patients are now more vocal and proactive, expressing a strong desire to be actively involved in their healthcare journey. This engagement reflects an increased awareness and understanding of their health needs and options, aligning with the personalised nature of precision medicine. In this blog, we examine precision medicine’s role in empowering patients to be more involved in their healthcare decisions, then explore how this shift is shaping the dynamics between healthcare providers and their patients.
In the rapidly evolving field of precision medicine, the role of patient engagement and communication is pivotal. As we venture into this new era of personalised healthcare, it's essential for pharmaceutical and biotech companies to establish trust and transparency with patients. This checklist serves as a guide to ensure companies are taking the right steps to effectively engage and communicate with patients participating in precision medicine research.
Natural history studies play a pivotal role in advancing our knowledge of diseases. These observational studies, which track the progression of diseases in their natural state without medical intervention, are particularly crucial in the realm of rare disease research. They serve as fundamental benchmarks against which the effectiveness of new treatments can be measured. In conducting these studies, extensive data is collected over an individual's lifetime, including initial diagnosis, clinical observations, and patient insights on quality of life. This rich tapestry of information provides a deep and nuanced understanding of how a disease progresses and its impact on those affected.
Last week, we attended the NASH-TAG conference in beautiful Park City, Utah. Against a winter wonderland backdrop, we dove deep into the latest research on metabolic associated steatohepatitis (MASH, also known as non-alcoholic steatohepatitis or NASH) and connected with leading experts in the field. Here, we’ll share some of our key learnings, underscoring the evolving landscape of liver disease research.
In the ever-changing field of precision medicine, continuous evaluation of data sharing and collaboration practices is essential for biotech and pharma companies. This ongoing assessment is vital to ensure compliance with evolving regulations, protect patient privacy, and foster innovative research. Drawing from our expertise in this area, we've created a straightforward checklist to help these companies responsibly handle genetic and biomarker data and collaborate effectively with third parties.